Pharmacokinetics

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

[Articles] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Addition of panitumumab to EOC chemotherapy does not increase overall survival and cannot be recommended for use in an unselected population with advanced oesophagogastric adenocarcinoma.

Treating adenocarcinoma with bevacizumab

Dr Ken O’Byrne discusses his talk at EMCTO 2013 in Lugano, Switzerland on how bevacizumab developed as a treatment for adenocarcinoma and other tumour types. Bevacizumab, which targets VGFR, origin...

Experimental Regimen Treatment Provides Equivalent Survival Rate to Standard Chemotherapy in Late-Stage Lung Cancer Patients

Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab fol...

[Comment] VEGF inhibition beyond tumour progression

In the past decade, treatment for advanced colorectal cancer has seen the introduction of biological agents like bevacizumab and cetuximab or panitumumab into standard palliative treatment with increm...

Standard chemotherapy provides higher survival rate than experimental in lung cancer patients

(American Society for Radiation Oncology) Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with p...

Standard chemotherapy provides equivalent survival rate to experimental in lung cancer patients

(American Society for Radiation Oncology) Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with p...

Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival

The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researche...

Breast cancer dug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane resea...

Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.

PURPOSE: To evaluate the pharmacokinetics of bevacizumab following IP and IV administration, and to investigate combined bevacizumab therapy (IP or IV) with IP paclitaxel or carboplatin in a mouse mod...

Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.

PURPOSE: The study characterizes the long-term pharmacokinetics (PK) following last dose of bevacizumab as adjuvant therapy in patients with resected stage II and III colon carcinoma in a Phase III cl...

Erythrodermic Psoriasis Improved by Panitumumab, But Not Bevacizumab.

Abstract is missing (Letter).

Pharmacokinetics, Lymph Node Uptake, and Mechanistic PK Model of Near-Infrared Dye-Labeled Bevacizumab After IV and SC Administration in Mice.

Our objective was to determine the pharmacokinetics, bioavailability and lymph node uptake of the monoclonal antibody bevacizumab, labeled with the near-infrared (IR) dye 800CW, after intravenous (IV)...

Feasibility of Eradication of Breast Cancer Cells Remaining in Postlumpectomy Cavity and Draining Lymph Nodes following Intracavitary Injection of Radioactive Immunoliposomes.

Most diagnosed early stage breast cancer cases are treated by lumpectomy and adjuvant radiation therapy, which significantly decreases the locoregional recurrence but causes inevitable toxicity to nor...